" PS to SI "after successful American venture/s! " +1 esp with MRSA becoming a major problem with resistance to Vancomycin"

Thanks for the update. MRSA strains developing Vancomycin resistance isn't a good news to the medical world. If tristel products are useful in preventing spread of MRSA, C.Diff and similar superbugs (there by reducing the morbidity rates), this company has a very bright future. It would be interesting to find any data about incidence of MRSA, before and after tristel products were introduced in various U.K. Hospitals.

Retired endoscopist/surgeon here. I did think there were big advantages to chlorine dioxide. Some years ago I tipped off my head of dept <at about 30p> and they trialled it. If there are multiple channels in a 'scope, as for through mouth and up other end, because you need to blow in air and also pass instruments, then there are better alternatives. If you are looking to wipe down an instrument (think back of nose) or clean other simple surfaces then it is very cost effective. To be honest my examinations of the cervix has been more social than professional but from the website:

it looks like this is a wipe down product and so a natural fit, so as to speak. The key is portability, no need for large tubs/vats pumps etc, just a packet of damp tissues.

Is this a charitable donation? My share of this company is miniscule but $750,000 is only about ten times the return I have already had from my few shares in TSTL and I would be happy that the company make a donation on my behalf. But professionally I would think this was sensible support and as a PI I am totally supportive. Further there must be thousands of potential EVA systems, not all nor even many of which need sterilization but for a simple example video dermatology has revolutionised the management of "moles" in many countries like UK, NZ and Auz.

Regards,

Seadoc

PS to SI "after successful American venture/s! " +1 esp with MRSA becoming a major problem with resistance to Vancomycin.

Not quite sure why you think they are being so charitable. The amount TSTL are putting up is a relatively small part of a much larger fund-raising by Mobile ODT. The stated objective is to pursue a partnership with Mobile ODT under which their kit is sold in a package with the disinfectant products which are essential for it. On the face of it this is a deal which could be quite reasonably called strategic. But I am not an endoscopy expert - I think we would all be happy to hear if you have better information.

Whilst laudable from an ethical viewpoint, I would suggest that Tristel's $750,000 investment in Mobile ODT borders on a charitable donation, looking at the markets Mobile ODT appears to be aiming at. However, I also notice a VC is investing so perhaps there is some investment sense there. Also a bit concerned about Tristel becoming involved with an early stage investment - I did not realise investing was part of the business plan. This may also have tax implications for some shareholders who benefit from the inheritance tax exemption for holdings in AIM companies. I would regard this as a radical and concerning departure from Tristel's normal business.

Yesterday, I visited tristel's display stall at Geneva palexpo. It was good. Out of nearly 100 display stalls showing pharma and medical equipments, many competing with each other, tristel stall was unique being only one of its kind. Hope the company does well.

Well, we shall know by tomorrow if there's any negative news on the way.

Quite a few well performing smallcaps in my portfolio fell today and I think a bout of profit taking is overdue. Perhaps this will continue for a while as prices are quite high. Not aware of any problems at Tristel.

We use the disinfectant in our hospital.
A peer -reviewed article from Australia was circulated last month, drawing attention to the risk of spores infecting ultrasound probes. (Just before the Aus licence was granted!)
Tristel products are more expensive than a quick wipe with an alcohol rag but what would you want inserted into a delicate area??
I know they are NOT used in 2 local hospitals so the market is far from saturated at home.
The big game-changer will be a US Licence (please Mr Trump)
I don't get in very often at the beginning of a growth story but this may be one (competition barring a cheaper effective alternative)

As a shareholder, I was very pleased with these results, particularly because of the rapidly increasing overseas sales. The next market to crack is of course the most valuable one (the US) and major success in this market would be transformative. The company's technology has been rigorously validated but there may nevertheless be delays in US sales as the company needs to jump through the hoops of the US regulatory system. I am sure the company has a Plan B in the event of any undue delays, such as forming a partnership with a potential US competitor or, bearing in mind the size of the US market, even selling out to a US major. However, I would much prefer the company to continue global expansion itself.

If you would like to hear management present the interim results for Tristel we will be hosting a webinar on Thursday 23rd February at 12.15pm. Paul Swinney, Chief Executive, and Liz Dixon, Finance Director, will give a presentation lasting approximately 30 mins and there will then be an opportunity for Q&A.

"LSE:TSTL:Tristel is perhaps unusual among smaller companies in publishing precise financial targets up to three years into the future. There's a danger that investors take them as a given, or extrapolate from them, even though they have yet to be ..."

" In recent months I've been reducing the number of criteria I use to judge an investment, and ensuring they are distinct from each other. The result is a template for what is, in my view, the perfect long-term investment. It should help me find ..."

Present spread is showing 5p, which is quite normal for TSTL. You may find that if you set up a dummy trade you will be offered better prices. I find the actual buy/sellprices are usually much closer than those shown on ii, so a smaller spread.

The SP has risen very strongly over the last month or so leading up to the results announcement last week. Results were expected to be good, and they didn't disappoint, being ahead of expectations. However, they did not drive the SP any further and I would expect latecomers to be taking profits.

IMHO, this is a well run company with good prospects and an open and approachable management. Once they get their US approvals this should further enhance their export potential and I would anticipate further upward progress in the SP. However, that's my opinion, not advice, and DYOR applies of course.

One final point about SP movement; it does have a habit of spiking down, only to return to the previous range, or better, reasonably quickly. It's up to the individual to consider if any such event presents a buying opportunity or a change of direction.

If you would like to hear management present the results for Tristel we will be hosting a webinar on Tuesday 18th October at 12.30pm. Paul Swinney, Chief Executive, and Liz Dixon, Finance Director, will give a presentation lasting approximately 30 mins and there will then be an opportunity for Q&A.

"... The strong cash generation also resulted in a special dividend of 3p per share.

Tristel is also debt free with a cash balance of £15.7mln.

The weakness in non-chlorine dioxide products did not fully materialise in H2 FY 2016 as we had expected, which together with continuing robust overseas growth, has led to upgrades to FY 2016 and 2017 forecasts, said analysts at finnCap.

The brokers forecast for profit before tax increased from £0.2m and £0.3m to £3.1m and £3.5m in 2016 and 2017 respectively.

The open day on 21st may provide some answers, but that's a long way off in this volatile market.
Having almost reached saturation sales point in the UK a lot of the hoped for growth depends on achieving regulatory approval in the States, as you have indicated. Paul Swinney put no time scale on that goal being achieved, and I suspect that there may be one or two hurdles delaying meaningful progress there. Brexit may have come into play there, though I hope not.

I am also a long term holder, and intend to add on further weakness. I like the open and investor friendly management style, and barring unforseen external calamities, am confident that steady rather than spectacular growth will be achieved. Nice and steady will do for me. As always, it's the timing that is difficult to predict.

High volumes to-day so maybe somebody is selling up , could bounce hard if the update is good but I don't think the market has yet forgiven the share based payments in the last accounts . America is all to play for but could be expensive so get approval etc. Been here a long time and not selling , might buy some more on further weakness but its hard to judge anything at the moment.

Having survived Brexit relatively unscathed the SP has taken a significant dive this week on no news that I can find. I would have thought that the weaker pound would have helped overseas sales, and domestic sales should not be affected. Any thoughts?

"Swinney said: We are very pleased with the platform we have built in Germany. The progress we have made in Europes largest hospital market is evident in the fact that Germanys contribution to group worldwide sales is now approaching 10 per cent. However, there is still enormous potential to exploit if the level of our German sales is to match the UKs. -

There is no guidance given regarding when US approvals may be achieved. Paul Swinney emphasised this in his presentation, and cited the uncertainty as his reason for the more reserved tone in growth prospects in any timeframe. The level of approval required for eachindividual product has to be decided, and the approval body to which submissions made confirmed. Then the necessary tests have to be run and the correct paperwork posted before we see tangible progress.
It could be 2016, but even if it is the market has to be started and sales growth established before it will affect the bottom line.
That said, I too topped up, but expect the SP to remain volatile until some of thespeculative unknowns are cleared away.

"The lesson for investors, is not to be seduced by management targets but recognise they are ambitions that may not be fulfilled. We should make our own, usually more conservative, expectations. Oh, and to scrutinise mundane looking announcements about share options more carefully."

------------------------------------------------------------------------------------------------
Sums up nicely the trap long term holders, myself included, fell into. In future I will pay more attention to those RNS notices awardingsignificant share options that have trigger points.

Now that is behind us, and I must say that Paul Swinney seemed genuinely embarassed by the event, even whilst pocketing the windfall, the share price should hopefully recover some lost ground.

I listened in to todays webinar and was impressed by the tone, transparency and clarity of the presentation. It has certainly clarified some aspects of the results and added explanation for some of the criticism arising.
Paul Swinney was emphatic that the share based payment is a one off, never to be repeated charge (caveated to at least not in the next 3-4 years).
The persieved slowdown in growth comes down to factors beyond Tristel control e.g. the time it will take for regulatory approval, particularly in the US, and a reluctance to forecast a growth that may take more time to crystailise than the predictiion period.
UK sales are more difficult to grow, mainly because of the current depth of market penetration, and the reluctance of faceless procurement staff in the NHS to embrace technology improvements for which there is no current budget.

On the whole a very positive presentation,with management continuing to be open with shareholders, and despite the recent savage SP fall has given me the confidence to top up my holding.
Recovery may be slow, but there seems to be no overiding business argument against it.

Important message from the Financial Conduct Authority:
Posting inside information that is not public knowledge, or information that is false or misleading, may constitute market abuse.
This could lead to an unlimited fine and up to seven years in prison.
If you have any information, concerns or queries about market abuse, click here.

The content of the messages posted represents the opinions of the author, and does not represent the opinions of Interactive Investor Trading Limited or its affiliates and has not been approved or issued by Interactive Investor Trading Limited.
You should be aware that the other participants of the above discussion group are strangers to you and may make statements which may be misleading, deceptive or wrong.
Please remember that the value of investments or income from them may go down as well as up and that the past performance of an investment is not a guide to its performance in the future.

The discussion boards on this site are intended to be an information sharing forum and is not intended to address your particular requirements.
Whilst information provided on them can help with your investment research you need to consider carefully whether you should make (or refraining from making) investment or other decisions based on what you see without doing further research on investments you are interested in.
Participating in this forum cannot be a substitute for obtaining advice from an appropriate expert independent adviser who takes into account your circumstances and specific investment needs in selected investments that are appropriate for you.

Popular Pages

Registered Office: Standon House, 21 Mansell Street, London E1 8AA, telephone 0345 200 3637. Registered in England with Company Registration number 3699618.
Group VAT registration number 832 6732 26.
We may record and/or monitor telephone calls or intercept other telecommunications between us. This is to protect both of us and for training purposes. Calls to this number cost no more than calls to 01 and 02 numbers.